Methods of enhancing anti-tumor immunity by administering antibodies to the CCRL2 chemerin receptor
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsBrian A. Zabel, Eugene C. Butcher, Russell K. Pachynski, Justin Monnier
Life of this patent
Estimating the term…
Abstract
Chemerin is a chemoattractant that selectively directs intra-tumor recruitment of CMKLR1+ cells. Blockade of CCRL2 from binding to chemerin in non-neoplastic tumor cells, e.g. peri-tumor stromal and/or hematopoietic cells allows for redistribution of chemerin into the tumor and enhanced responsiveness against a tumor.
Claims6
A method of enhancing immune response to an epithelial tumor in an individual wherein non-neoplastic cells express C-C chemokine receptor-like 2 (CCRL2), the method comprising:
- administering a monoclonal antibody that reduces the binding of CCRL2 to chemerin and prevents CCRL2 from sequestering chemerin, in a dose effective to increase the bioavailability of chemerin, resulting in an enhancement of anti-cancer activity by the individual's immune system.
A method of enhancing immune response to melanoma in an individual wherein non-neoplastic cells express CCRL2, the method comprising:
- administering a monoclonal antibody that reduces the binding of CCRL2 to chemerin and prevents CCRL2 from sequestering chemerin, in a dose effective to increase the bioavailability of chemerin, resulting in an enhancement of anti-cancer activity by the individual's immune system.
Dependencies are inferred from the claim text.